Full Text View
Tabular View
No Study Results Posted
Related Studies
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
This study has been completed.
Study NCT00066781   Information provided by National Cancer Institute (NCI)
First Received: August 6, 2003   Last Updated: April 14, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma of Unknown Primary
Additional conditions recognized in this trial
Carcinoma
Neoplasms, Unknown Primary
More general conditions related to this trial
Neoplasm Metastasis
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplastic Processes
Pathologic Processes
Interventions listed in this trial
gemcitabine hydrochloride
irinotecan hydrochloride
Additional drug interventions recognized in this trial
Camptothecin
Gemcitabine
Irinotecan
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
North Central Cancer Treatment Group
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services